Role of Fatty Acids in the Pathogenesis of Obesity and Fatty Liver: Impact of Bariatric Surgery

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) spans a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) to cirrhosis. Simple steatosis is the substrate upon which the more serious entities in the spectrum develop; it is the first “hit” in the multistep pathogenesis of NASH, which is considered the hepatic manifestation of the metabolic syndrome. Demonstration of the existence of regulatable fatty acid transport mechanisms has contributed to clarifying the role of fatty acid disposition in obesity, the various components of NAFLD, and the metabolic syndrome. Hepatic steatosis is closely linked to obesity. This linkage is based on the fact that obesity results in marked enlargement of the intraabdominal visceral fat depots. The eventual development of insulin resistance leads to continuous lipolysis within these depots, releasing fatty acids into the portal circulation, where they are rapidly translocated to the liver and reassembled into triglycerides. Reactive oxygen species, generated in the liver from oxidation of fatty acids, are precipitating factors in the cascade of events leading from simple steatosis to NASH. Dysregulation of fatty acid disposition, with ectopic lipid accumulation in other tissues, is a major contributing factor to other components of the metabolic syndrome. Bariatric surgery is an effective treatment for severe obesity, but its role in the management of the various forms of fatty liver disease is unclear. Our review of the literature that includes both initial and follow-up liver biopsies suggests that most obese patients with simple steatosis and NASH who undergo bariatric surgery will achieve improvement in hepatic histology, but that occasional patients, especially those who lose weight very rapidly, may show worsening of either fibrosis or steatohepatitis.

KEYWORDS

Obesity - type 2 diabetes mellitus - hepatic steatosis - nonalcoholic fatty liver disease - steatohepatitis - NAFLD - NASH

REFERENCES

• 1 The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity—2001. Washington, DC; Goverment Printing Office, U.S. Department of Health and Human Services 2001
• 2 Yanovski S Z, Yanovski J A. Obesity.  N Engl J Med. 2002;  346(8) 591-602
• 3 Flegal K M, Carroll M D, Ogden C L, Johnson C L. Prevalence and trends in obesity among US adults, 1999–2000.  JAMA. 2002;  288(14) 1723-1727
• 4 Ogden C L, Yanovski S Z, Carroll M D, Flegal K M. The epidemiology of obesity.  Gastroenterology. 2007;  132(6) 2087-2102
• 5 State-specific prevalence of obesity among adults—United States, 2005.  MMWR Morb Mortal Wkly Rep. 2006;  55(36) 985-988
• 6 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology. 1990;  12(5) 1106-1110
• 7 Clark J M, Brancati F L, Diehl A M. The prevalence and etiology of elevated aminotransferase levels in the United States.  Am J Gastroenterol. 2003;  98(5) 960-967
• 8 Ruhl C E, Everhart J E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.  Gastroenterology. 2003;  124(1) 71-79
• 9 Ruhl C E, Everhart J E. Epidemiology of nonalcoholic fatty liver.  Clin Liver Dis. 2004;  8(3) 501-519
• 10 Browning J D, Szczepaniak L S, Dobbins R et al.. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.  Hepatology. 2004;  40(6) 1387-1395
• 11 Clark J M. The epidemiology of nonalcoholic fatty liver disease in adults.  J Clin Gastroenterol. 2006;  40(suppl 1) S5-S10
• 12 Kopelman P G. Obesity as a medical problem.  Nature. 2000;  404(6778) 635-643
• 13 Ogden C L, Carroll M D, Curtin L R, McDowell M A, Tabak C J, Flegal K M. Prevalence of overweight and obesity in the United States, 1999–2004.  JAMA. 2006;  295(13) 1549-1555
• 14 Ogden C L, McDowell M A, Flegal K M. Obesity among adults in the United States: no change since 2003–2004. NCHS Data Brief #1. Hyattsville, MD; National Center for Health Statistics 2007
• 15 Danaei G, Vander Hoorn S, Lopez A D, Murray C J, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors.  Lancet. 2005;  366(9499) 1784-1793
• 16 Kleiner D E, Brunt E M, Van Natta M et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.  Hepatology. 2005;  41(6) 1313-1321
• 17 Bondini S, Kleiner D E, Goodman Z D, Gramlich T, Younossi Z M. Pathologic assessment of non-alcoholic fatty liver disease.  Clin Liver Dis. 2007;  11(1) 17-23
• 18 Yeh M M, Brunt E M. Pathology of nonalcoholic fatty liver disease.  Am J Clin Pathol. 2007;  128(5) 837-847
• 19 Brunt E M. Nonalcoholic steatohepatitis: definition and pathology.  Semin Liver Dis. 2001;  21(1) 3-16
• 20 Brunt E M, Neuschwander-Tetri B A, Oliver D, Wehmeier K R, Bacon B R. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.  Hum Pathol. 2004;  35(9) 1070-1082
• 21 Brunt E M. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis.  Semin Diagn Pathol. 2005;  22(4) 330-338
• 22 Thung S N, Gerber M. Alcoholic hepatitis vs nonalcoholic steatohepatitis. In: Thung SN, Gerber MA Differential Diagnosis in Pathology: Liver Disorders. New York; Igaku-Shoin 1995: 24-36
• 23 Pinto H C, Baptista A, Camilo M E, Valente A, Saragoca A, de Moura M C. Nonalcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.  Dig Dis Sci. 1996;  41(1) 172-179
• 24 Gramlich T, Kleiner D E, McCullough A J, Matteoni C A, Boparai N, Younossi Z M. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.  Hum Pathol. 2004;  35(2) 196-199
• 25 Leclercq I A, Horsmans Y. Cell biology of NASH: fibrosis and cell proliferation. In: Farrell GC, George J, Hall P de la M, McCullough AK Fatty Liver Disease: NASH and Related Disorders. Oxford; Blackwell 2005: 143-158
• 26 Powell E E, Cooksley W G, Hanson R, Searle J, Halliday J W, Powell L W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.  Hepatology. 1990;  11(1) 74-80
• 27 Teli M R, James O F, Burt A D, Bennett M K, Day C P. The natural history of nonalcoholic fatty liver: a follow-up study.  Hepatology. 1995;  22(6) 1714-1719
• 28 Matteoni C A, Younossi Z M, Gramlich T, Boparai N, Liu Y C, McCullough A J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology. 1999;  116(6) 1413-1419
• 29 Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.  Hepatology. 2004;  40(4) 820-826
• 30 Adams L A, Sanderson S, Lindor K D, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.  J Hepatol. 2005;  42(1) 132-138
• 31 Adams L A, Lymp J F, St Sauver J et al.. The natural history of nonalcoholic fatty liver disease: a population-based cohort study.  Gastroenterology. 2005;  129(1) 113-121
• 32 Gholam P M, Flancbaum L, Machan J T, Charney D A, Kotler D P. Nonalcoholic fatty liver disease in severely obese subjects.  Am J Gastroenterol. 2007;  102(2) 399-408
• 33 Clark J M, Diehl A M. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis.  JAMA. 2003;  289(22) 3000-3004
• 34 Caldwell S H, Crespo D M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease.  J Hepatol. 2004;  40(4) 578-584
• 35 Caldwell S HHA. The clinical outcome of NAFLD including cryptogenic cirrhosis. In: Farrell GC, George J, Hall P de la M, McCullough AK Fatty Liver Disease: NASH and Related Disorders. Oxford; Blackwell 2005: 168-180
• 36 Farrell G C, Larter C Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.  Hepatology. 2006;  43(suppl 1) S99-S112
• 37 Charlton M, Kasparova P, Weston S et al.. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.  Liver Transpl. 2001;  7(7) 608-614
• 38 Burke A, Lucey M R. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation.  Am J Transplant. 2004;  4(5) 686-693
• 39 Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact.  Clin Gastroenterol Hepatol. 2004;  2(12) 1048-1058
• 40 Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.  Best Pract Res Clin Gastroenterol. 2004;  18(6) 1105-1116
• 41 Rafiq N, Younossi Z M. Effects of weight loss on nonalcoholic fatty liver disease.  Semin Liver Dis. 2008;  28 427-433
• 42 Belfort R, Harrison S A, Brown K et al.. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.  N Engl J Med. 2006;  355(22) 2297-2307
• 43 Ghali P, Lindor K D. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.  Semin Liver Dis. 2004;  24(4) 389-397
• 44 Neuschwander-Tetri B A. Nonalcoholic steatohepatitis and the metabolic syndrome.  Am J Med Sci. 2005;  330(6) 326-335
• 45 Grattagliano I, Portincasa P, Palmieri V O, Palasciano G. Managing nonalcoholic fatty liver disease: recommendations for family physicians.  Can Fam Physician. 2007;  53(5) 857-863
• 46 Kadayifci A, Merriman R B, Bass N M. Medical treatment of non-alcoholic steatohepatitis.  Clin Liver Dis. 2007;  11(1) 119-140 ix
• 47 Clark J M. Weight loss as a treatment for nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2006;  40(suppl 1) S39-S43
• 48 Stremmel W, Berk P D. Hepatocellular influx of [14C]oleate reflects membrane transport rather than intracellular metabolism or binding.  Proc Natl Acad Sci U S A. 1986;  83(10) 3086-3090
• 49 Schwieterman W, Sorrentino D, Potter B J et al.. Uptake of oleate by isolated rat adipocytes is mediated by a 40-kDa plasma membrane fatty acid binding protein closely related to that in liver and gut.  Proc Natl Acad Sci U S A. 1988;  85(2) 359-363
• 50 Sorrentino D, Stump D, Potter B J et al.. Oleate uptake by cardiac myocytes is carrier mediated and involves a 40-kD plasma membrane fatty acid binding protein similar to that in liver, adipose tissue, and gut.  J Clin Invest. 1988;  82(3) 928-935
• 51 Stremmel W. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein.  J Clin Invest. 1988;  82(6) 2001-2010
• 52 Nunes R M, Isola L M, Sorrentino D, Berk P D. Oleate uptake by isolated hepatocytes consists of two components, each driven by the unbound oleate concentration. In: Proceedings of the 3rd International Congress, Mathematical Modelling of Liver Excretory Process Tokyo; Juntendo University Press 1990: 312-316
• 53 Stump D D, Nunes R M, Sorrentino D, Isola L M, Berk P D. Characteristics of oleate binding to liver plasma membranes and its uptake by isolated hepatocytes.  J Hepatol. 1992;  16(3) 304-315
• 54 Berk P D, Stump D D. Mechanisms of cellular uptake of long chain free fatty acids.  Mol Cell Biochem. 1999;  192(1–2) 17-31
• 55 Stump D D, Fan X, Berk P D. Oleic acid uptake and binding by rat adipocytes define dual pathways for cellular fatty acid uptake.  J Lipid Res. 2001;  42(4) 509-520
• 56 Stoll G H, Voges R, Gerok W, Kurz G. Synthesis of a metabolically stable modified long-chain fatty acid salt and its photolabile derivative.  J Lipid Res. 1991;  32(5) 843-857
• 57 Schmider W, Fahr A, Blum H E, Kurz G. Transport of heptafluorostearate across model membranes: membrane transport of long-chain fatty acid anions I.  J Lipid Res. 2000;  41(5) 775-787
• 58 Abumrad N A, Perkins R C, Park J H, Park C R. Mechanism of long chain fatty acid permeation in the isolated adipocyte.  J Biol Chem. 1981;  256(17) 9183-9191
• 59 Abumrad N A, Park J H, Park C R. Permeation of long-chain fatty acid into adipocytes: kinetics, specificity, and evidence for involvement of a membrane protein.  J Biol Chem. 1984;  259(14) 8945-8953
• 60 Weisiger R A, Fitz J G, Scharschmidt B F. Hepatic oleate uptake: electrochemical driving forces in intact rat liver.  J Clin Invest. 1989;  83(2) 411-420
• 61 Glatz J F, van Nieuwenhoven F A, Luiken J J, Schaap F G, van der Vusse G J. Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism.  Prostaglandins Leukot Essent Fatty Acids. 1997;  57(4–5) 373-378
• 62 Luiken J J, Turcotte L P, Bonen A. Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles.  J Lipid Res. 1999;  40(6) 1007-1016
• 63 Luiken J J, Glatz J F, Bonen A. Fatty acid transport proteins facilitate fatty acid uptake in skeletal muscle.  Can J Appl Physiol. 2000;  25(5) 333-352
• 64 Kampf J P, Kleinfeld A M. Fatty acid transport in adipocytes monitored by imaging intracellular free fatty acid levels.  J Biol Chem. 2004;  279(34) 35775-35780
• 65 Kleinfeld A M, Kampf J P, Lechene C. Transport of 13C-oleate in adipocytes measured using multi imaging mass spectrometry.  J Am Soc Mass Spectrom. 2004;  15(11) 1572-1580
• 66 Stremmel W, Strohmeyer G, Borchard F, Kochwa S, Berk P D. Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes.  Proc Natl Acad Sci U S A. 1985;  82(1) 4-8
• 67 Bradbury M W, Berk P D. Cellular uptake of long chain free fatty acids: the structure and function of plasma membrane fatty acid binding protein.  Adv Mol Cell Biol. 2004;  33 47-81
• 68 Berk P D, Wada H, Horio Y et al.. Plasma membrane fatty acid-binding protein and mitochondrial glutamic-oxaloacetic transaminase of rat liver are related.  Proc Natl Acad Sci U S A. 1990;  87(9) 3484-3488
• 69 Stump D D, Zhou S L, Berk P D. Comparison of plasma membrane FABP and mitochondrial isoform of aspartate aminotransferase from rat liver.  Am J Physiol. 1993;  265(5 Pt 1) G894-G902
• 70 Abumrad N A, el-Maghrabi M R, Amri E Z, Lopez E, Grimaldi P A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation: homology with human CD36.  J Biol Chem. 1993;  268(24) 17665-17668
• 71 Schaffer J E, Lodish H F. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein.  Cell. 1994;  79(3) 427-436
• 72 Hirsch D, Stahl A, Lodish H F. A family of fatty acid transporters conserved from mycobacterium to man.  Proc Natl Acad Sci U S A. 1998;  95(15) 8625-8629
• 73 Stahl A, Gimeno R E, Tartaglia L A, Lodish H F. Fatty acid transport proteins: a current view of a growing family.  Trends Endocrinol Metab. 2001;  12(6) 266-273
• 74 Trigatti B L, Anderson R G, Gerber G E. Identification of caveolin-1 as a fatty acid binding protein.  Biochem Biophys Res Commun. 1999;  255(1) 34-39
• 75 Pohl J, Ring A, Stremmel W. Uptake of long-chain fatty acids in HepG2 cells involves caveolae: analysis of a novel pathway.  J Lipid Res. 2002;  43(9) 1390-1399
• 76 Kampf J P, Parmley D, Kleinfeld A M. Free fatty acid transport across adipocytes is mediated by an unknown membrane protein pump.  Am J Physiol Endocrinol Metab. 2007;  293(5) E1207-E1214
• 77 Berk P D, Zhou S L, Kiang C L, Stump D, Bradbury M, Isola L M. Uptake of long chain free fatty acids is selectively up-regulated in adipocytes of Zucker rats with genetic obesity and non-insulin-dependent diabetes mellitus.  J Biol Chem. 1997;  272(13) 8830-8835
• 78 Berk P D, Zhou S L, Bradbury M, Stump D, Kiang C L, Isola L M. Regulated membrane transport of free fatty acids in adipocytes: role in obesity and non-insulin dependent diabetes mellitus.  Trans Am Clin Climatol Assoc. 1997;  108 26-40 , discussion 41–43
• 79 Berk P D, Zhou S, Kiang C, Stump D D, Fan X, Bradbury M W. Selective up-regulation of fatty acid uptake by adipocytes characterizes both genetic and diet-induced obesity in rodents.  J Biol Chem. 1999;  274(40) 28626-28631
• 80 Petrescu O, Fan X, Gentileschi P et al.. Long-chain fatty acid uptake is upregulated in omental adipocytes from patients undergoing bariatric surgery for obesity.  Int J Obes (Lond). 2005;  29(2) 196-203
• 81 Bradbury M W, Berk P D. Lipid metabolism in hepatic steatosis.  Clin Liver Dis. 2004;  8(3) 639-671 xi
• 82 Lee G H, Proenca R, Montez J M et al.. Abnormal splicing of the leptin receptor in diabetic mice.  Nature. 1996;  379(6566) 632-635
• 83 Chua Jr S C, Chung W K, Wu-Peng X S et al.. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor.  Science. 1996;  271(5251) 994-996
• 84 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372(6505) 425-432
• 85 Fan X, Bradbury M W, Berk P D. Leptin and insulin modulate nutrient partitioning and weight loss in ob/ob mice through regulation of long-chain fatty acid uptake by adipocytes.  J Nutr. 2003;  133(9) 2707-2715
• 86 Lee Y, Wang M Y, Kakuma T et al.. Liporegulation in diet-induced obesity: the antisteatotic role of hyperleptinemia.  J Biol Chem. 2001;  276(8) 5629-5635
• 87 Unger R H. Lipotoxic diseases.  Annu Rev Med. 2002;  53 319-336
• 88 Unger R H. The physiology of cellular liporegulation.  Annu Rev Physiol. 2003;  65 333-347
• 89 Halaas J L, Gajiwala K S, Maffei M et al.. Weight-reducing effects of the plasma protein encoded by the obese gene.  Science. 1995;  269(5223) 543-546
• 90 Pelleymounter M A, Cullen M J, Baker M B et al.. Effects of the obese gene product on body weight regulation in ob/ob mice.  Science. 1995;  269(5223) 540-543
• 91 Campfield L A, Smith F J, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks.  Science. 1995;  269(5223) 546-549
• 92 Remesar X, Rafecas I, Fernandez-Lopez J A, Alemany M. Is leptin an insulin counter-regulatory hormone?.  FEBS Lett. 1997;  402(1) 9-11
• 93 Myers M G, Cowley M A, Munzberg H. Mechanisms of leptin action and leptin resistance.  Annu Rev Physiol. 2008;  70 537-556
• 94 Oh-I S, Shimizu H, Sato T, Uehara Y, Okada S, Mori M. Molecular mechanisms associated with leptin resistance: n-3 polyunsaturated fatty acids induce alterations in the tight junction of the brain.  Cell Metab. 2005;  1(5) 331-341
• 95 Listenberger L L, Ory D S, Schaffer J E. Palmitate-induced apoptosis can occur through a ceramide-independent pathway.  J Biol Chem. 2001;  276(18) 14890-14895
• 96 Unger R H, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders.  FASEB J. 2001;  15(2) 312-321
• 97 Unger R H. Minireview: weapons of lean body mass destruction—the role of ectopic lipids in the metabolic syndrome.  Endocrinology. 2003;  144(12) 5159-5165
• 98 Schaffer J E. Lipotoxicity: when tissues overeat.  Curr Opin Lipidol. 2003;  14(3) 281-287
• 99 Shimomura I, Hammer R E, Ikemoto S, Brown M S, Goldstein J L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.  Nature. 1999;  401(6748) 73-76
• 100 Bray G A. Medical consequences of obesity.  J Clin Endocrinol Metab. 2004;  89(6) 2583-2589
• 101 Reaven G M. Role of insulin resistance in human disease (syndrome X): an expanded definition.  Annu Rev Med. 1993;  44 121-131
• 102 Reaven G M. Pathophysiology of insulin resistance in human disease.  Physiol Rev. 1995;  75(3) 473-486
• 103 Dunbar R L, Rader D J. Slaying the metabolic syndrome: are we battling the Hydra or the Chimera?.  Minerva Endocrinol. 2004;  29(3) 89-111
• 104 Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease.  Circulation. 2002;  106(3) 286-288
• 105 Freedland E S. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review.  Nutr Metab (Lond). 2004;  1(1) 12
• 106 Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity.  Clin Liver Dis. 2004;  8(3) 535-547
• 107 Choudhury J, Sanyal A J. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease.  Clin Liver Dis. 2004;  8(3) 575-594 ix
• 108 Marceau P, Biron S, Hould F S et al.. Liver pathology and the metabolic syndrome X in severe obesity.  J Clin Endocrinol Metab. 1999;  84(5) 1513-1517
• 109 Pagano G, Pacini G, Musso G et al.. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.  Hepatology. 2002;  35(2) 367-372
• 110 Wisse B E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.  J Am Soc Nephrol. 2004;  15(11) 2792-2800
• 111 Kerner A, Avizohar O, Sella R et al.. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome.  Arterioscler Thromb Vasc Biol. 2005;  25(1) 193-197
• 112 Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity.  Curr Atheroscler Rep. 2004;  6(6) 424-431
• 113 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.  Circulation. 2002;  106(25) 3143-3421
• 114 Grundy S M, Hansen B, Smith Jr S C, Cleeman J I, Kahn R A. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management.  Arterioscler Thromb Vasc Biol. 2004;  24(2) e19-e24
• 115 Grundy S M, Brewer Jr H B, Cleeman J I, Smith Jr S C, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.  Arterioscler Thromb Vasc Biol. 2004;  24(2) e13-e18
• 116 Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2005;  28(9) 2289-2304
• 117 Reaven G M. The individual components of the metabolic syndrome: is there a raison d'etre?.  J Am Coll Nutr. 2007;  26(3) 191-195
• 118 Chirieac D V, Chirieac L R, Corsetti J P, Cianci J, Sparks C E, Sparks J D. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production.  Am J Physiol Endocrinol Metab. 2000;  279(5) E1003-E1011
• 119 Diehl A M. Lessons from animal models of NASH.  Hepatol Res. 2005;  33(2) 138-144
• 120 Yamaguchi K, Yang L, McCall S et al.. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.  Hepatology. 2007;  45(6) 1366-1374
• 121 Zhou S L, Gordon R E, Bradbury M, Stump D, Kiang C L, Berk P D. Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in HepG2 cells.  Hepatology. 1998;  27(4) 1064-1074
• 122 Berk P D, Zhou S, Bradbury M W. Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings.  Trans Am Clin Climatol Assoc. 2005;  116 335-344 , discussion 345
• 123 Day C P, James O F. Steatohepatitis: a tale of two “hits”?.  Gastroenterology. 1998;  114(4) 842-845
• 124 McCullough A J. Pathophysiology of nonalcoholic steatohepatitis.  J Clin Gastroenterol. 2006;  40(suppl 1) S17-S29
• 125 Merriman R B, Aouizerat B E, Bass N M. Genetic influences in nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2006;  40(suppl 1) S30-S33
• 126 Mantena S K, King A L, Andringa K K, Eccleston H B, Bailey S M. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases.  Free Radic Biol Med. 2008;  44(7) 1259-1272
• 127 Malhi H, Gores G J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease.  Semin Liver Dis. 2008;  28 360-369
• 128 Jou J, Choi S S, Diehl A M. Mechanisms of disease progression in nonalcoholic fatty liver disease.  Semin Liver Dis. 2008;  28 370-379
• 129 Charlton M. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon.  Am J Gastroenterol. 2007;  102(2) 409-411
• 130 Leclercq I A, Farrell G C, Field J, Bell D R, Gonzalez F J, Robertson G R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.  J Clin Invest. 2000;  105(8) 1067-1075
• 131 Robertson G, Leclercq I, Farrell G C. Nonalcoholic steatosis and steatohepatitis: II. Cytochrome P-450 enzymes and oxidative stress.  Am J Physiol Gastrointest Liver Physiol. 2001;  281(5) G1135-G1139
• 132 Sanyal A J, Campbell-Sargent C, Mirshahi F et al.. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.  Gastroenterology. 2001;  120(5) 1183-1192
• 133 Chitturi S, Abeygunasekera S, Farrell G C et al.. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome.  Hepatology. 2002;  35(2) 373-379
• 134 Chitturi S, Farrell G, Frost L et al.. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?.  Hepatology. 2002;  36(2) 403-409
• 135 Hui J M, Hodge A, Farrell G C, Kench J G, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?.  Hepatology. 2004;  40(1) 46-54
• 136 Puri P, Baillie R A, Wiest M M et al.. A lipidomic analysis of nonalcoholic fatty liver disease.  Hepatology. 2007;  46(4) 1081-1090
• 137 Puri P, Mirshahi F, Cheung O et al.. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.  Gastroenterology. 2008;  134(2) 568-576
• 138 Bray G A. Drug treatment of obesity.  Rev Endocr Metab Disord. 2001;  2(4) 403-418
• 139 Klein S, Wadden T, Sugerman H J. AGA technical review on obesity.  Gastroenterology. 2002;  123(3) 882-932
• 140 Anderson J W, Konz E C, Frederich R C, Wood C L. Long-term weight-loss maintenance: a meta-analysis of US studies.  Am J Clin Nutr. 2001;  74(5) 579-584
• 141 Wadden T A, Foster G D. Behavioral treatment of obesity.  Med Clin North Am. 2000;  84(2) 441-461 vii
• 142 National Institutes of Health . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The Evidence Report.  Obes Res. 1998;  6(suppl 2) 51S-209S
• 143 Leibel R L, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight.  N Engl J Med. 1995;  332(10) 621-628
• 144 Weinsier R L, Nagy T R, Hunter G R, Darnell B E, Hensrud D D, Weiss H L. Do adaptive changes in metabolic rate favor weight regain in weight-reduced individuals? An examination of the set-point theory.  Am J Clin Nutr. 2000;  72(5) 1088-1094
• 145 Mason E E, Ito C. Gastric bypass in obesity.  Surg Clin North Am. 1967;  47(6) 1345-1351
• 146 Hubbard V S, Hall W H. Gastrointestinal surgery for severe obesity.  Obes Surg. 1991;  1(3) 257-265
• 147 Zhao Y, Encinosa W. Agency for Healthcare Research and Quality (AHRQ), Bariatric Surgery Utilization and Outcomes in 1998 and 2004. Statistical Brief # 23. Rockville, MD; Agency or Healthcare Quality and Research 2007
• 148 NIDDK Working group on bariatric surgery: executive summary (2002). American Society for Bariatric Surgery. Rationale for the surgical treatment of morbid obesity. Available at: http://www.asbs.org/html/rationale/rationale.html Accessed April 14, 2008
• 149 Brolin R E. Gastric bypass.  Surg Clin North Am. 2001;  81(5) 1077-1095
• 150 Pories W J, Swanson M S, MacDonald K G et al.. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus.  Ann Surg. 1995;  222(3) 339-350 , discussion 350–352
• 151 Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus.  Ann Surg. 2002;  236(5) 554-559
• 152 Kral J G, Naslund E. Surgical treatment of obesity.  Nat Clin Pract Endocrinol Metab. 2007;  3(8) 574-583
• 153 Elder K A, Wolfe B M. Bariatric surgery: a review of procedures and outcomes.  Gastroenterology. 2007;  132(6) 2253-2271
• 154 Buchwald H. A bariatric surgery algorithm.  Obes Surg. 2002;  12(6) 733-746 , discussion 747–750
• 155 Regan J, Selzer D J, Inabnet W B. Choosing the right laparoscopic bariatric surgical procedure. In: Inabnet WB, DeMaria EJ, Ikramuddin S Laparoscopic Bariatric Surgery. Philadelphia; Lippincott Williams and Wilkins 2004: 47-54
• 156 Belle S H, Berk P D, Courcoulas A P et al.. Safety and efficacy of bariatric surgery: longitudinal assessment of bariatric surgery.  Surg Obes Relat Dis. 2007;  3(2) 116-126
• 157 DeMaria E J, Jamal M K. Laparoscopic adjustable gastric banding: evolving clinical experience.  Surg Clin North Am. 2005;  85(4) 773-787 vii
• 158 Gagner M, Inabnet W B, Pomp A. Laparoscopic sleeve gastrectomy with second stage biliopancreatic diversion and duodenal switch in the superobese. In: Inabnet WB, DeMaria EJ, Ikramuddin S Laparoscopic Bariatric Surgery. Philadelphia; Lippincott Williams and Wilkins 2004: 143-150
• 159 Scharf M T, Ahima R S. Gut peptides and other regulators in obesity.  Semin Liver Dis. 2004;  24(4) 335-347
• 160 Murphy K G, Dhillo W S, Bloom S R. Gut peptides in the regulation of food intake and energy homeostasis.  Endocr Rev. 2006;  27(7) 719-727
• 161 Wren A M, Bloom S R. Gut hormones and appetite control.  Gastroenterology. 2007;  132(6) 2116-2130
• 162 Chaudhri O B, Salem V, Murphy K G, Bloom S R. Gastrointestinal satiety signals.  Annu Rev Physiol. 2008;  70 239-255
• 163 de Fatima Haueisen Sander Diniz M, de Azeredo Passos V M, Diniz M T. Gut-brain communication: how does it stand after bariatric surgery?.  Curr Opin Clin Nutr Metab Care. 2006;  9(5) 629-636
• 164 le Roux C W, Aylwin S J, Batterham R L et al.. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.  Ann Surg. 2006;  243(1) 108-114
• 165 le Roux C W, Welbourn R, Werling M et al.. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass.  Ann Surg. 2007;  246(5) 780-785
• 166 Wren A M, Seal L J, Cohen M A et al.. Ghrelin enhances appetite and increases food intake in humans.  J Clin Endocrinol Metab. 2001;  86(12) 5992
• 167 Cummings D E, Weigle D S, Frayo R S et al.. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.  N Engl J Med. 2002;  346(21) 1623-1630
• 168 Nakazato M, Murakami N, Date Y et al.. A role for ghrelin in the central regulation of feeding.  Nature. 2001;  409(6817) 194-198
• 169 Korner J, Inabnet W, Conwell I M et al.. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels.  Obesity (Silver Spring). 2006;  14(9) 1553-1561
• 170 Foschi D, Corsi F, Colombo F et al.. Different effects of vertical banded gastroplasty and Roux-en-Y gastric bypass on meal inhibition of ghrelin secretion in morbidly obese patients.  J Invest Surg. 2008;  21(2) 77-81
• 171 Kotidis E V, Koliakos G G, Baltzopoulos V G, Ioannidis K N, Yovos J G, Papavramidis S T. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment—a prospective study.  Obes Surg. 2006;  16(11) 1425-1432
• 172 Chan J L, Mun E C, Stoyneva V, Mantzoros C S, Goldfine A B. Peptide YY levels are elevated after gastric bypass surgery.  Obesity (Silver Spring). 2006;  14(2) 194-198
• 173 Brolin R E, Bradley L J, Taliwal R V. Unsuspected cirrhosis discovered during elective obesity operations.  Arch Surg. 1998;  133(1) 84-88
• 174 Drenick E J, Simmons F, Murphy J F. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass.  N Engl J Med. 1970;  282(15) 829-834
• 175 Marubbio Jr A T, Buchwald H, Schwartz M Z, Varco R. Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass.  Am J Clin Pathol. 1976;  66(4) 684-691
• 176 Campbell J M, Hunt T K, Karam J H, Forsham P H. Jejunoileal bypass as a treatment of morbid obesity.  Arch Intern Med. 1977;  137(5) 602-610
• 177 Vyberg M, Ravn V, Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity.  Liver. 1987;  7(5) 271-276
• 178 Hocking M P, Duerson M C, O'Leary J P, Woodward E R. Jejunoileal bypass for morbid obesity: late follow-up in 100 cases.  N Engl J Med. 1983;  308(17) 995-999
• 179 Marubbio A T, Rucker Jr R D, Schneider P D, Horstmann J P, Varco R L, Buchwald H. The liver in morbid obesity and following bypass surgery for obesity.  Surg Clin North Am. 1979;  59(6) 1079-1093
• 180 DeWind L T, Payne J H. Intestinal bypass surgery for morbid obesity: long-term results.  JAMA. 1976;  236(20) 2298-2301
• 181 Andersen T, Gluud C, Franzmann M B, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects.  J Hepatol. 1991;  12(2) 224-229
• 182 Drenick E J, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass: prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition.  Gastroenterology. 1982;  82(3) 535-548
• 183 Siegmund S V, Dooley S, Brenner D A. Molecular mechanisms of alcohol-induced hepatic fibrosis.  Dig Dis. 2005;  23(3–4) 264-274
• 184 Ruiz A G, Casafont F, Crespo J et al.. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis.  Obes Surg. 2007;  17(10) 1374-1380
• 185 Meinhardt N G, Souto K E, Ulbrich-Kulczynski J M, Stein A T. Hepatic outcomes after jejunoileal bypass: is there a publication bias?.  Obes Surg. 2006;  16(9) 1171-1178
• 186 Wills C E. Long-term follow-up of jejunoileal bypass patients with preoperative cirrhosis of the liver.  Obes Surg. 1994;  4(1) 37-39
• 187 Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity.  Digestion. 1990;  47(4) 208-214
• 188 Grimm I S, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion.  Am J Gastroenterol. 1992;  87(6) 775-779
• 189 Silverman E M, Sapala J A, Appelman H D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass.  Am J Clin Pathol. 1995;  104(1) 23-31
• 190 Dixon J B, Bhathal P S, Hughes N R, O'Brien P E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss.  Hepatology. 2004;  39(6) 1647-1654
• 191 Luyckx F H, Desaive C, Thiry A et al.. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty.  Int J Obes Relat Metab Disord. 1998;  22(3) 222-226
• 192 Kral J G, Thung S N, Biron S et al.. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.  Surgery. 2004;  135(1) 48-58
• 193 Clark J M, Alkhuraishi A R, Solga S F, Alli P, Diehl A M, Magnuson T H. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.  Obes Res. 2005;  13(7) 1180-1186
• 194 Stratopoulos C, Papakonstantinou A, Terzis I et al.. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity.  Obes Surg. 2005;  15(8) 1154-1160
• 195 Mattar S G, Velcu L M, Rabinovitz M et al.. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.  Ann Surg. 2005;  242(4) 610-617 , discussion 618–620
• 196 Mottin C C, Moretto M, Padoin A V et al.. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery.  Obes Surg. 2005;  15(6) 788-793
• 197 de Almeida S R, Rocha P R, Sanches M D et al.. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity.  Obes Surg. 2006;  16(3) 270-278
• 198 Klein S, Mittendorfer B, Eagon J C et al.. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease.  Gastroenterology. 2006;  130(6) 1564-1572
• 199 Jaskiewicz K, Raczynska S, Rzepko R, Sledzinski Z. Nonalcoholic fatty liver disease treated by gastroplasty.  Dig Dis Sci. 2006;  51(1) 21-26
• 200 Barker K B, Palekar N A, Bowers S P, Goldberg J E, Pulcini J P, Harrison S A. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.  Am J Gastroenterol. 2006;  101(2) 368-373
• 201 Mathurin P, Gonzalez F, Kerdraon O et al.. The evolution of severe steatosis after bariatric surgery is related to insulin resistance.  Gastroenterology. 2006;  130(6) 1617-1624
• 202 Csendes A, Smok G, Burgos A M. Histological findings in the liver before and after gastric bypass.  Obes Surg. 2006;  16(5) 607-611
• 203 Dixon J B, Bhathal P S, O'Brien P E. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.  Obes Surg. 2006;  16(10) 1278-1286
• 204 Liu X, Lazenby A J, Clements R H, Jhala N, Abrams G A. Resolution of nonalcoholic steatohepatits after gastric bypass surgery.  Obes Surg. 2007;  17(4) 486-492
• 205 Furuya Jr C K, de Oliveira C P, de Mello E S et al.. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.  J Gastroenterol Hepatol. 2007;  22(4) 510-514
• 206 Flum D R, Dellinger E P. Impact of gastric bypass operation on survival: a population-based analysis.  J Am Coll Surg. 2004;  199(4) 543-551
• 207 Sampalis J S, Liberman M, Auger S, Christou N V. The impact of weight reduction surgery on health-care costs in morbidly obese patients.  Obes Surg. 2004;  14(7) 939-947
• 208 Adams T D, Gress R E, Smith S C et al.. Long-term mortality after gastric bypass surgery.  N Engl J Med. 2007;  357(8) 753-761
• 209 Sjostrom L, Narbro K, Sjostrom C D et al.. Effects of bariatric surgery on mortality in Swedish obese subjects.  N Engl J Med. 2007;  357(8) 741-752
• 210 Bray G A. The missing link: lose weight, live longer.  N Engl J Med. 2007;  357(8) 818-820